Windward Bio’s next-generation antibody drugs for immunology caught the interest of Sanofi, which bought shares in a private placement alongside the biotech’s IPO. Windward’s lead drug candidate addresses the same target as a blockbuster asthma drug from partners Amgen and AstraZeneca.
The post Windward Bio’s Stock Market Debut Reels In $225M for Better Biologic Drugs appeared first on MedCity News.
